MA34923B1 - Anticorps humains contre pcsk9 pour utilisation dans des procedes de traitement de groupes particuliers de sujets - Google Patents

Anticorps humains contre pcsk9 pour utilisation dans des procedes de traitement de groupes particuliers de sujets

Info

Publication number
MA34923B1
MA34923B1 MA36205A MA36205A MA34923B1 MA 34923 B1 MA34923 B1 MA 34923B1 MA 36205 A MA36205 A MA 36205A MA 36205 A MA36205 A MA 36205A MA 34923 B1 MA34923 B1 MA 34923B1
Authority
MA
Morocco
Prior art keywords
pcsk9
antibodies
antigen
specific
treatment
Prior art date
Application number
MA36205A
Other languages
English (en)
Inventor
Corinne Hanotin
Laurence Bessac
Umesh Chaudhari
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45529125&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34923(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP11305089A external-priority patent/EP2481758A1/fr
Priority claimed from EP11305088.4A external-priority patent/EP2650016A1/fr
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MA34923B1 publication Critical patent/MA34923B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)

Abstract

La présente invention concerne des procédés pour traiter des maladies ou des affections dans lesquelles l'expression ou l'activité de proprotéine convertase subtilisine/kexine type 9 (PCSK9) a un impact par administration d'anticorps spécifiques pour PCSK9 ou de fragments de liaison d'antigène de ceux-ci et de préférence par administration additionnelle d'un inhibiteur de 3-hydroxy-3-méthyl-glutaryl-CoA réductase (HMG-CoA réductase). La présente invention concerne en outre des anticorps spécifiques pour PCSK9 ou des fragments de liaison d'antigène de ceux-ci pour utilisation dans le traitement de maladies ou affections dans lesquelles l'expression ou l'activité de PCSK9 a un impact. La présente invention concerne en outre des articles de fabrication comprenant un matériau d'emballage, des anticorps spécifiques pour PCSK9 ou des fragments de liaison d'antigène de ceux-ci, et une étiquette ou une notice d'utilisation indiquant quels groupes de patients peuvent être traités avec lesdits anticorps ou fragments, quels groupes de traitement ne doivent pas être traités avec lesdits anticorps ou fragments, et quel régime posologique doit être utilisé. La présente invention concerne en outre des procédés d'essai de l'efficacité d'anticorps spécifiques pour PCSK9 ou des fragments de liaison d'antigène de ceux-ci pour le traitement de certaines maladies ou affections et pour le traitement de sous-groupes spécifiques de patients.
MA36205A 2011-01-28 2013-08-27 Anticorps humains contre pcsk9 pour utilisation dans des procedes de traitement de groupes particuliers de sujets MA34923B1 (fr)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
EP11305089A EP2481758A1 (fr) 2011-01-28 2011-01-28 Anticorps humains anti-PSCK9 pour une utilisation dans des procédés de traitement des groupes de sujets particuliers (11566)
EP11305088.4A EP2650016A1 (fr) 2011-01-28 2011-01-28 Anticorps humains anti-PSCK9 pour une utilisation dans des procédés de traitement basés sur des régimes de dosage particuliers (11565)
EP11305514 2011-04-29
EP11305513 2011-04-29
EP11306039 2011-08-12
EP11306040 2011-08-12
EP11306201 2011-09-22
EP11306202 2011-09-22
EP11306449 2011-11-08
EP11306450 2011-11-08
PCT/EP2012/051320 WO2012101252A2 (fr) 2011-01-28 2012-01-27 Anticorps humains contre pcsk9 pour utilisation dans des procédés de traitement de groupes particuliers de sujets

Publications (1)

Publication Number Publication Date
MA34923B1 true MA34923B1 (fr) 2014-02-01

Family

ID=45529125

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36205A MA34923B1 (fr) 2011-01-28 2013-08-27 Anticorps humains contre pcsk9 pour utilisation dans des procedes de traitement de groupes particuliers de sujets

Country Status (37)

Country Link
US (7) US9561155B2 (fr)
EP (4) EP2668212B1 (fr)
JP (8) JP6375113B2 (fr)
KR (6) KR20220136466A (fr)
CN (4) CN110711248A (fr)
AR (3) AR084939A1 (fr)
AU (5) AU2012210480B2 (fr)
BR (2) BR112013018740A2 (fr)
CA (2) CA2825778A1 (fr)
CL (2) CL2013002162A1 (fr)
CO (2) CO6751276A2 (fr)
CR (1) CR20130406A (fr)
CY (1) CY1121236T1 (fr)
DK (1) DK2668212T3 (fr)
DO (1) DOP2013000170A (fr)
EC (1) ECSP13012792A (fr)
ES (3) ES2674600T3 (fr)
GT (1) GT201300186A (fr)
HR (1) HRP20180959T1 (fr)
HU (1) HUE039258T2 (fr)
IL (5) IL227657B (fr)
LT (1) LT2668212T (fr)
MA (1) MA34923B1 (fr)
MX (5) MX366458B (fr)
MY (2) MY176600A (fr)
NI (1) NI201300064A (fr)
PE (2) PE20140372A1 (fr)
PH (3) PH12013501576A1 (fr)
PL (3) PL2668212T3 (fr)
PT (1) PT2668212T (fr)
RS (1) RS57339B1 (fr)
RU (4) RU2721279C2 (fr)
SG (2) SG192117A1 (fr)
SI (1) SI2668212T1 (fr)
TW (3) TWI625127B (fr)
WO (3) WO2012101252A2 (fr)
ZA (2) ZA201305524B (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11306155B2 (en) 2014-07-16 2022-04-19 Sanofi Biotechnology Methods for treating patients with heterozygous familial hypercholesterolemia (heFH) with an anti-PCSK9 antibody
US11673967B2 (en) 2011-07-28 2023-06-13 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-PCSK9 antibodies
US11904017B2 (en) 2015-08-18 2024-02-20 Regeneron Pharmaceuticals, Inc. Methods for reducing or eliminating the need for lipoprotein apheresis in patients with hyperlipidemia by administering alirocumab
US12083176B2 (en) 2011-01-28 2024-09-10 Sanofi Biotechnology Human antibodies to PCSK9 for use in methods of treating particular groups of subjects
US12269897B2 (en) 2008-12-15 2025-04-08 Regeneron Pharmaceuticals, Inc. Anti-PCSK9 antibodies
US12606638B2 (en) 2013-11-12 2026-04-21 Sanofi Biotechnology Dosing regimens for use with PCSK9 inhibitors

Families Citing this family (142)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20080381B1 (ar) * 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
KR101913109B1 (ko) 2009-03-18 2018-10-31 리스버로직스 코퍼레이션 신규한 소염제
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
BR112014000392A2 (pt) * 2011-07-14 2017-02-21 Pfizer tratamento com anticorpos anti-pcsk9
HUE069234T2 (hu) 2011-09-16 2025-02-28 Regeneron Pharma Eljárások lipoprotein(a)-szint csökkentésére proprotein-konvertáz szubtilizin/kexin 9 (PCSK9) inhibitorának beadásával
EA039663B1 (ru) 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
EP2861624A1 (fr) 2012-06-15 2015-04-22 F. Hoffmann-La Roche AG Anticorps anti-pcsk9, formulations, dosage, et méthodes d'utilisation
US9540449B2 (en) 2012-08-13 2017-01-10 Regeneron Pharmaceuticals, Inc. Anti-PCSK9 antibodies with pH-dependent binding characteristics
EP2703008A1 (fr) * 2012-08-31 2014-03-05 Sanofi Anticorps humains anti-PSCK9 pour une utilisation dans des procédés de traitement des groupes de sujets particuliers
EP2703009A1 (fr) * 2012-08-31 2014-03-05 Sanofi Traitements combinés impliquant des anticorps de la PCSK9 humaine
EP2706070A1 (fr) * 2012-09-06 2014-03-12 Sanofi Traitements combinés impliquant des anticorps de la PCSK9 humaine
ES2860954T3 (es) 2012-11-21 2021-10-05 Amgen Inc Dispositivo de administración de fármacos
US10646664B2 (en) 2013-03-15 2020-05-12 Amgen Inc. Body contour adaptable autoinjector device
JP6336564B2 (ja) 2013-03-15 2018-06-06 アムゲン・インコーポレーテッド 薬物カセット、自動注入器、および自動注入器システム
TWI614041B (zh) 2013-03-15 2018-02-11 安美基公司 用於注射器之匣盒
WO2014149357A1 (fr) 2013-03-22 2014-09-25 Amgen Inc. Injecteur et procédé d'assemblage
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
EP2810955A1 (fr) * 2013-06-07 2014-12-10 Sanofi Procédés pour inhiber l'athérosclérose par l'administration d'un inhibiteur de PCSK9
ES2901400T3 (es) * 2013-06-07 2022-03-22 Regeneron Pharma Métodos para inhibir la ateroesclerosis administrando un inhibidor de PCSK9
US10494442B2 (en) * 2013-06-07 2019-12-03 Sanofi Biotechnology Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9
EP2862877A1 (fr) * 2013-10-18 2015-04-22 Sanofi Procédés pour inhiber l'athérosclérose par l'administration d'un inhibiteur de PCSK9
CA2916259C (fr) * 2013-06-28 2024-02-20 Amgen Inc. Procedes de traitement d'une hypercholesterolemie familiale homozygote
US20160367651A1 (en) * 2013-10-01 2016-12-22 Mie University T cell inducing vaccine containing an interepitope sequence that promotes antigen presentation
ES2914978T3 (es) * 2013-10-11 2022-06-20 Sanofi Biotechnology Uso de un inhibidor de PCSK9 para tratar hiperlipidemia
ES2779126T3 (es) * 2013-10-11 2020-08-13 Sanofi Biotechnology Uso de un inhibidor de PCSK9 para tratar hiperlipidemia
CA3168888A1 (fr) 2013-10-24 2015-04-30 Amgen Inc. Systeme de distribution de medicaments equipe d'un dispositif de commande sensible a la temperature
SG11201602876WA (en) 2013-10-24 2016-05-30 Amgen Inc Injector and method of assembly
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US9067998B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting PD-1 variants for treatment of cancer
US9034332B1 (en) 2014-07-15 2015-05-19 Kymab Limited Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
US9051378B1 (en) 2014-07-15 2015-06-09 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US8883157B1 (en) 2013-12-17 2014-11-11 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
US9023359B1 (en) 2014-07-15 2015-05-05 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US9045548B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
DE112014005975T5 (de) * 2013-12-17 2016-09-15 Kymab Limited Menschliche Ziele
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
US8945560B1 (en) 2014-07-15 2015-02-03 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US10994112B2 (en) 2014-02-05 2021-05-04 Amgen Inc. Drug delivery system with electromagnetic field generator
EA201691320A1 (ru) * 2014-02-14 2016-11-30 Ридженерон Фармасьютикалз, Инк. Способы лечения пациентов с гиперхолестеринемией, которая устойчива к терапии умеренными дозами статинов
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
WO2015140079A1 (fr) * 2014-03-17 2015-09-24 Sanofi Methodes pour traiter des sujets atteints d'hypercholestérolémie primaire qui n'est pas prise en charge de manière adéquate
US10872313B2 (en) 2015-06-02 2020-12-22 ROCA Medical Ltd. Method for repurposing NDC codes in a pharmaceutical database for venom derived allergens involved in venom immunotherapy
AU2015256082C1 (en) 2014-05-07 2020-09-10 Amgen Inc. Autoinjector with shock reducing elements
CN111840696B (zh) 2014-06-03 2022-12-20 安姆根有限公司 可控制药物递送系统和使用方法
AU2015289874A1 (en) * 2014-07-14 2017-02-02 Amgen Inc. Crystalline antibody formulations
US9150660B1 (en) 2014-07-15 2015-10-06 Kymab Limited Precision Medicine by targeting human NAV1.8 variants for treatment of pain
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
CA2955304C (fr) * 2014-07-16 2023-12-12 Sanofi Biotechnology Methodes de traitement de patients presentant un risque cardiovasculaire eleve avec hypercholesterolemie
WO2016046684A1 (fr) 2014-09-23 2016-03-31 Pfizer Inc. Traitement avec des anticorps anti-pcsk9
EP3206739B1 (fr) 2014-10-14 2021-12-01 Amgen Inc. Dispositif d'injection de médicament comportant des témoins visuels et sonores
EP3848072A1 (fr) 2014-12-19 2021-07-14 Amgen Inc. Dispositif d'administration de médicament comportant un capteur de proximité
US11357916B2 (en) 2014-12-19 2022-06-14 Amgen Inc. Drug delivery device with live button or user interface field
JP6484345B2 (ja) 2015-02-17 2019-03-20 アムジエン・インコーポレーテツド 固定及び／または戻りが真空によって支援された薬物送達装置
EA039310B1 (ru) * 2015-02-26 2022-01-12 Санофи Байотекнолоджи Способы снижения сердечно-сосудистого риска
WO2016138434A1 (fr) 2015-02-27 2016-09-01 Amgen Inc. Dispositif d'administration de médicament ayant un mécanisme de protection d'aiguille présentant un seuil réglable de résistance au mouvement de l'élément de protection d'aiguille
EP3271405A1 (fr) * 2015-03-20 2018-01-24 Aarhus Universitet Inhibiteurs de pcsk9 pour le traitement de troubles du métabolisme des lipoprotéines
CN104861071B (zh) * 2015-04-27 2019-04-12 南京师范大学 针对pcsk9的全人源单克隆抗体的可变区基因及其应用
US10548974B2 (en) * 2015-06-02 2020-02-04 ROCA Medical Ltd. Therapeutic treatment kit for allergies based on DNA profiles
WO2017039786A1 (fr) 2015-09-02 2017-03-09 Amgen Inc. Adaptateur d'ensemble de seringue pour une seringue
CN105348390B (zh) * 2015-10-26 2018-08-28 北京智仁美博生物科技有限公司 抗人pcsk9单克隆抗体
JP7082568B2 (ja) 2015-12-09 2022-06-08 アムジエン・インコーポレーテツド 信号伝達キャップ付き自動注射器
EP3398968B1 (fr) 2015-12-31 2024-06-12 Jiangsu Hengrui Medicine Co., Ltd. Anticorps anti-pcsk9, fragment de liaison à l'antigène associé et application médicale associée
CN107531795B (zh) 2016-01-05 2021-01-19 江苏恒瑞医药股份有限公司 Pcsk9抗体、其抗原结合片段及其医药用途
US11154661B2 (en) 2016-01-06 2021-10-26 Amgen Inc. Auto-injector with signaling electronics
AU2017216653B2 (en) 2016-02-08 2021-12-23 Kyoto University Pretreatment drug for T cell infusion therapy for immune-checkpoint inhibitor-resistant tumor
DK3429663T3 (da) 2016-03-15 2020-09-28 Amgen Inc Reduktion af sandsynligheden for glasbrud i anordninger til indgivelse af lægemidler
WO2017189089A1 (fr) 2016-04-29 2017-11-02 Amgen Inc. Dispositif d'administration de médicament avec étiquette de messagerie
US11389588B2 (en) 2016-05-02 2022-07-19 Amgen Inc. Syringe adapter and guide for filling an on-body injector
AU2017263558B2 (en) 2016-05-13 2022-12-22 Amgen Inc. Vial sleeve assembly
WO2017200989A1 (fr) 2016-05-16 2017-11-23 Amgen Inc. Chiffrement de données dans des dispositifs médicaux à capacité de calcul limitée
US11541176B2 (en) 2016-06-03 2023-01-03 Amgen Inc. Impact testing apparatuses and methods for drug delivery devices
RU2769282C2 (ru) 2016-06-20 2022-03-30 Кимаб Лимитед Анти-PD-L1 и IL-2 цитокины
EP3478342B1 (fr) 2016-07-01 2025-03-12 Amgen Inc. Dispositif d'administration de médicament présentant un risque réduit au minimum de fracture de composant lors d'événements d'impact
WO2018034784A1 (fr) 2016-08-17 2018-02-22 Amgen Inc. Dispositif d'administration de médicament avec détection de positionnement.
EP3525820A4 (fr) * 2016-10-17 2020-09-16 Vanderbilt University Anticorps contre le virus respiratoire syncytial humain et leurs méthodes d'utilisation
US20200261643A1 (en) 2016-10-25 2020-08-20 Amgen Inc. On-body injector
JOP20190095A1 (ar) 2016-10-27 2019-04-28 Janssen Pharmaceutica Nv مركبات ببتيد تيروسين-تيروسين الحلقية كمعدلات لمستقبلات الببتيد العصبي y
EP3534947A1 (fr) 2016-11-03 2019-09-11 Kymab Limited Anticorps, combinaisons comprenant des anticorps, biomarqueurs, utilisations et procédés
AU2018210301A1 (en) 2017-01-17 2019-08-01 Amgen Inc. Injection devices and related methods of use and assembly
CA3052204A1 (fr) 2017-02-17 2018-08-23 Amgen Inc. Mecanisme d'insertion pour dispositif d'administration de medicament
WO2018151890A1 (fr) 2017-02-17 2018-08-23 Amgen Inc. Dispositif d'administration de médicament à trajet d'écoulement de fluide stérile et procédé d'assemblage associé
EP3592403B1 (fr) 2017-03-06 2025-08-20 Amgen Inc. Dispositif d'administration de médicaments doté d'une fonction de prévention d'activation
US11571511B2 (en) 2017-03-07 2023-02-07 Amgen Inc. Insertion mechanism and method of inserting a needle of a drug delivery device
AU2018230486B2 (en) 2017-03-09 2023-05-11 Amgen Inc. Insertion mechanism for drug delivery device
ES3023742T3 (en) 2017-03-28 2025-06-03 Amgen Inc Plunger rod and syringe assembly system
JP7050807B2 (ja) 2017-04-13 2022-04-08 カディラ ヘルスケア リミティド 新規ペプチドベースのｐｃｓｋ９ワクチン
US11590294B2 (en) 2017-06-08 2023-02-28 Amgen Inc. Syringe assembly for a drug delivery device and method of assembly
JP7200134B2 (ja) 2017-06-08 2023-01-06 アムジエン・インコーポレーテツド トルク駆動式薬物送達デバイス
JP7195276B2 (ja) 2017-06-22 2022-12-23 アムジエン・インコーポレーテツド デバイス起動による衝突／衝撃の低減
WO2018237225A1 (fr) 2017-06-23 2018-12-27 Amgen Inc. Dispositif électronique d'administration de médicament comprenant un bouchon activé par un ensemble commutateur
IL270784B2 (en) 2017-07-14 2023-11-01 Amgen Inc Needle insertion-extraction system with a double torsion spring system
JP7649105B2 (ja) 2017-07-21 2025-03-19 アムジエン・インコーポレーテツド 薬物容器のためのガス透過性シーリング部材及び組立方法
MA49676A (fr) 2017-07-25 2020-06-03 Amgen Inc Dispositif d'administration de médicament doté d'un système d'accès à un récipient et procédé d'assemblage associé
US11617837B2 (en) 2017-07-25 2023-04-04 Amgen Inc. Drug delivery device with gear module and related method of assembly
MA49838A (fr) 2017-08-09 2020-06-17 Amgen Inc Systèm de administration de médicaments avec pression hydraulique-pneumatique de chambre
EP3668567B1 (fr) 2017-08-18 2026-02-18 Amgen Inc. Injecteur portable avec patch adhésif stérile
US11103636B2 (en) 2017-08-22 2021-08-31 Amgen Inc. Needle insertion mechanism for drug delivery device
WO2019070472A1 (fr) 2017-10-04 2019-04-11 Amgen Inc. Adaptateur d'écoulement destiné à un dispositif d'administration de médicament
ES2971450T3 (es) 2017-10-06 2024-06-05 Amgen Inc Dispositivo de administración de fármacos con conjunto de enclavamiento y procedimiento de montaje correspondiente
US11464903B2 (en) 2017-10-09 2022-10-11 Amgen Inc. Drug delivery device with drive assembly and related method of assembly
IL273582B2 (en) 2017-11-03 2024-12-01 Amgen Inc Systems and approaches for sterilizing a drug delivery device
EP3706830B1 (fr) 2017-11-06 2024-08-07 Amgen Inc. Dispositif d'administration de médicament avec détection de positionnement et de débit
EP3707075A1 (fr) 2017-11-06 2020-09-16 Amgen Inc. Ensembles de remplissage-finition et procédés associés
MA50557A (fr) 2017-11-10 2020-09-16 Amgen Inc Pistons pour dispositifs d'administration de médicament
JP7370969B2 (ja) 2017-11-16 2023-10-30 アムジエン・インコーポレーテツド 薬物送達デバイスの扉ラッチ機構
MX2020005066A (es) 2017-11-16 2020-08-20 Amgen Inc Autoinyector con deteccion de detencion y punto final.
JP6639463B2 (ja) * 2017-12-21 2020-02-05 アムジエン・インコーポレーテツド ホモ接合性家族性高コレステロール血症の治療方法
TW201945401A (zh) * 2018-03-06 2019-12-01 法商賽諾菲生物技術公司 降低心血管風險的方法
EA202092778A1 (ru) * 2018-05-16 2021-05-27 ЛИБ ТЕРАПЬЮТИКС, ЭлЭлСи Композиции, содержащие pcsk9-связывающие молекулы, и способы применения
CN112512480B (zh) * 2018-05-21 2024-10-01 中外制药株式会社 被封入玻璃容器的冷冻干燥制剂
US10835685B2 (en) 2018-05-30 2020-11-17 Amgen Inc. Thermal spring release mechanism for a drug delivery device
US11083840B2 (en) 2018-06-01 2021-08-10 Amgen Inc. Modular fluid path assemblies for drug delivery devices
CA3103681A1 (fr) 2018-07-24 2020-01-30 Amgen Inc. Dispositifs d'administration pour l'administration de medicaments
MA53375A (fr) 2018-07-24 2021-06-02 Amgen Inc Dispositifs d'administration pour l'administration de médicaments
WO2020023336A1 (fr) 2018-07-24 2020-01-30 Amgen Inc. Dispositifs hybrides d'administration de médicament dotés d'une partie de préhension
US12303677B2 (en) 2018-07-24 2025-05-20 Amgen Inc. Hybrid drug delivery devices with optional grip portion and related method of preparation
CA3103105A1 (fr) 2018-07-31 2020-02-06 Amgen Inc. Ensemble de trajet de fluide pour dispositif d'administration de medicament
US20210346601A1 (en) 2018-09-24 2021-11-11 Amgen Inc. Interventional dosing systems and methods
CA3110371A1 (fr) 2018-09-28 2020-04-02 Amgen Inc. Ensemble d'activation d'echappement de fil de muscle pour un dispositif d'administration de medicament
EP3860685A1 (fr) 2018-10-02 2021-08-11 Amgen Inc. Systèmes d'injection pour administration de médicament avec transmission de force interne
US12151089B2 (en) 2018-10-05 2024-11-26 Amgen Inc. Drug delivery device having dose indicator
WO2020081480A1 (fr) 2018-10-15 2020-04-23 Amgen Inc. Procédé d'assemblage de plate-forme pour dispositif d'administration de médicament
TW202541859A (zh) 2018-10-15 2025-11-01 美商安進公司 具有阻尼機構之藥物遞送裝置及自動注射器
MA54048A (fr) 2018-11-01 2022-02-09 Amgen Inc Dispositifs d'administration de médicament avec rétraction partielle de l'organe d'administration de médicament
TWI831847B (zh) 2018-11-01 2024-02-11 美商安進公司 部分針頭縮回之藥物遞送裝置及其操作方法
EP3873563A1 (fr) 2018-11-01 2021-09-08 Amgen Inc. Dispositifs d'administration de médicament à rétraction partielle d'élément d'administration de médicament
BR112021013807A2 (pt) 2019-01-18 2021-11-30 Astrazeneca Ab Inibidores de pcsk9 e seus métodos de uso
WO2020167910A1 (fr) * 2019-02-12 2020-08-20 Amgen Inc. Systèmes et approches pour la reconstitution d'un dispositif d'administration de médicament
AU2020263289B2 (en) 2019-04-24 2025-05-22 Amgen Inc. Syringe sterilization verification assemblies and methods
EP3969620B1 (fr) 2019-05-17 2025-06-25 Regeneron Pharmaceuticals, Inc. Procédés basés sur le génome pour réduire le risque cardiovasculaire
WO2021041067A2 (fr) 2019-08-23 2021-03-04 Amgen Inc. Dispositif d'administration de médicament doté de composants configurables de mise en prise de protection d'aiguille et méthodes associées
WO2021076825A1 (fr) * 2019-10-18 2021-04-22 Amgen Inc. Systèmes et approches pour la reconstitution d'un dispositif d'administration de médicament
JP2021041262A (ja) * 2020-12-17 2021-03-18 株式会社三洋物産 遊技機
JP2024523779A (ja) 2021-05-21 2024-07-02 アムジェン インコーポレイテッド 薬物容器用の充填レシピを最適化する方法
WO2026030152A1 (fr) 2024-07-29 2026-02-05 Amgen Inc. Système et procédé d'évaluation de la transférabilité d'une recette de remplissage

Family Cites Families (183)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0747045B2 (ja) 1986-10-15 1995-05-24 株式会社大協精工 積層した注射器用滑栓
US5670373A (en) 1988-01-22 1997-09-23 Kishimoto; Tadamitsu Antibody to human interleukin-6 receptor
CA1341152C (fr) 1988-01-22 2000-12-12 Tadamitsu Kishimoto Proteine du recepteur du facteur d'induction des cellules humaines b2
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US5016784A (en) 1990-02-15 1991-05-21 Dexus Research Inc. Applicator for highly reactive materials
US5795965A (en) 1991-04-25 1998-08-18 Chugai Seiyaku Kabushiki Kaisha Reshaped human to human interleukin-6 receptor
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
AU2309692A (en) 1991-07-03 1993-02-11 Cryolife, Inc. Method for stabilization of biomaterials
JP3100727B2 (ja) 1992-01-23 2000-10-23 株式会社大協精工 変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品
WO1993022336A1 (fr) 1992-04-30 1993-11-11 Alpha Therapeutic Corporation Solubilisation et stabilisation ameliorees du complexe du facteur viii
WO1994009138A1 (fr) 1992-10-20 1994-04-28 Cetus Oncology Corporation Antagonistes du recepteur d'interleukine 6
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
US5888511A (en) 1993-02-26 1999-03-30 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including AIDS
US5888510A (en) 1993-07-21 1999-03-30 Chugai Seiyaku Kabushiki Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
GB9410534D0 (en) 1994-05-26 1994-07-13 Lynxvale Ltd Improvements in or relating to growth factor inhibitors
CN1306963C (zh) 1994-10-21 2007-03-28 岸本忠三 用于治疗il－6产生所致疾病的药物组合物
EP0800829B2 (fr) 1994-12-29 2012-07-25 Chugai Seiyaku Kabushiki Kaisha Utilisation d'un anticorps pm-1 ou d'un anticorps mh 166 pour potentialiser l'effet antitumoral de la cisplatine ou de la carboplatine
EP0811384B1 (fr) 1995-02-13 2006-06-21 Chugai Seiyaku Kabushiki Kaisha Inhibiteur de decomposition des proteines musculaires contenant un anticorps du recepteur de l'interleukine-6
JP3172057B2 (ja) 1995-04-05 2001-06-04 株式会社大協精工 ラミネートゴム栓
ES2434840T3 (es) 1995-07-27 2013-12-17 Genentech, Inc. Formulación de proteína liofilizada isotónica estable
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
JPH09154588A (ja) 1995-10-07 1997-06-17 Toagosei Co Ltd Ｖｅｇｆ結合性ポリペプチド
CA2250570A1 (fr) 1996-03-26 1997-10-02 Eli Lilly And Company Formulations de proteine ob
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US6692742B1 (en) 1996-06-27 2004-02-17 Chugai Seiyaku Kabushiki Kaisha Remedies for myeloma to be used together with nitrogen mustard antitumor agents
EP0852951A1 (fr) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Compositions pharmaceutiques stables, lyophilisées d'anticorps monoclonaux ou polyclonaux
US7312196B2 (en) 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US20070224663A1 (en) 1997-03-07 2007-09-27 Human Genome Sciences, Inc. Human Secreted Proteins
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US20020187150A1 (en) 1997-08-15 2002-12-12 Chugai Seiyaku Kabushiki Kaisha Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient
JP4549529B2 (ja) 1998-01-30 2010-09-22 サイオス，インコーポレーテッド ペプチドまたはタンパク質の制御放出送達
CN100374159C (zh) 1998-03-17 2008-03-12 中外制药株式会社 一种包含il-6拮抗剂活性成分的炎性肠道疾病的预防或治疗剂
JP3512349B2 (ja) 1999-01-29 2004-03-29 株式会社大協精工 柱状ゴム要素の成形型
US7001892B1 (en) 1999-06-11 2006-02-21 Purdue Research Foundation Pharmaceutical materials and methods for their preparation and use
US7129338B1 (en) 1999-07-08 2006-10-31 Research Association For Biotechnology Secretory protein or membrane protein
EP1514933A1 (fr) 1999-07-08 2005-03-16 Research Association for Biotechnology Protéine sécrétoire ou protéine de membrane
US7029895B2 (en) 1999-09-27 2006-04-18 Millennium Pharmaceuticals, Inc. 27411, a novel human PGP synthase
DE60025744D1 (de) 1999-10-07 2006-04-13 Lilly Co Eli Kondensierte dihydrochinolinon-derivate zur hemmung von mrp1
EP1257572A2 (fr) 2000-02-07 2002-11-20 Millennium Pharmaceuticals, Inc. Nouveaux homologues de type subtilase (narc-1)
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
US7148197B2 (en) 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
MXPA03002045A (es) 2000-09-08 2003-07-24 Amgen Inc Composiciones analogas de factor estimulador de colonias de granulocitos y metodos para su elaboracion.
AU2002213441B2 (en) 2000-10-12 2006-10-26 Genentech, Inc. Reduced-viscosity concentrated protein formulations
CN1259973C (zh) 2000-10-25 2006-06-21 中外制药株式会社 含有il－6拮抗剂作为有效成分的牛皮癣的预防或治疗剂
JP4889187B2 (ja) 2000-10-27 2012-03-07 中外製薬株式会社 Ｉｌ−６アンタゴニストを有効成分として含有する血中ｍｍｐ−３濃度低下剤
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
JP2002209975A (ja) 2001-01-19 2002-07-30 Daikyo Seiko Ltd 医薬バイアル用ラミネートゴム栓
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
MXPA04000747A (es) 2001-07-25 2004-07-08 Protein Desing Labs Inc Formulacion farmaceutica liofilizada estable de anticuerpos igg.
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
US20060078533A1 (en) 2004-10-12 2006-04-13 Omoigui Osemwota S Method of prevention and treatment of aging and age-related disorders including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimer's disease and cancer
US20060078532A1 (en) 2004-10-12 2006-04-13 Omoigui Osemwota S Method of prevention and treatment of Atherosclerosis, Peripheral vascular disease, Coronary artery disease, aging and age-related disorders including osteoporosis, arthritis, type 2 diabetes, dementia and Alzheimer's disease
US20060078531A1 (en) 2004-10-12 2006-04-13 Osemwota Sota Method of prevention and treatment of atherosclerosis, peripheral vascular disease, coronary artery disease, and age-related disorders including osteoporosis, arthritis, type 2 diabetes, dementia and Alzheimer's disease
US20060275294A1 (en) 2002-08-22 2006-12-07 Omoigui Osemwota S Method of prevention and treatment of aging, age-related disorders and/or age-related manifestations including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimers disease and cancer
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
AU2003293543A1 (en) 2002-12-13 2004-07-09 Abgenix, Inc. System and method for stabilizing antibodies with histidine
US7534427B2 (en) 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
MXPA05010555A (es) 2003-04-04 2006-03-09 Genentech Inc Formulaciones de proteina y anticuerpo de alta concentracion.
EP1471152A1 (fr) 2003-04-25 2004-10-27 Institut National De La Sante Et De La Recherche Medicale (Inserm) Mutations du gène humain PCSK9 qui sont associées à la hypercholesterolemia
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
DE10355251A1 (de) 2003-11-26 2005-06-23 Merck Patent Gmbh Pharmazeutische Zubereitung enthaltend einen Antikörper gegen den EGF-Rezeptor
AR048210A1 (es) 2003-12-19 2006-04-12 Chugai Pharmaceutical Co Ltd Un agente preventivo para la vasculitis.
ATE464908T1 (de) 2004-02-11 2010-05-15 Warner Lambert Co Verfahren zur behandlung von osteoarthritis mit anti-il-6 antikörpern
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
AU2005287406B2 (en) 2004-07-26 2011-08-18 Biogen Ma Inc. Anti-CD154 antibodies
US20110313024A1 (en) 2004-08-20 2011-12-22 Leonid Beigelman RNA INTERFERENCE MEDIATED INHIBITION OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9 (PCSK9) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20070036788A1 (en) 2004-09-22 2007-02-15 Ahmed Sheriff Use of a compound for reducing the biological effectiveness of il-6
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US20060177436A1 (en) 2004-12-16 2006-08-10 Genentech, Inc. Methods for Treating Autoimmune Disorders
US20060147945A1 (en) 2005-01-06 2006-07-06 Edmonds Brian T Novel secreted proteins and their uses
AU2006318583A1 (en) 2005-11-22 2007-05-31 Wyeth Immunoglobulin fusion protein formulations
US20080131374A1 (en) 2006-04-19 2008-06-05 Medich John R Uses and compositions for treatment of rheumatoid arthritis
ES2366974T3 (es) 2006-05-05 2011-10-27 Isis Pharmaceuticals, Inc. Compuestos y procedimientos para modular la expresión de sglt2.
JP2009536222A (ja) 2006-05-05 2009-10-08 アイシス ファーマシューティカルズ， インコーポレーテッド Ｐｃｓｋ９の発現を調節するための化合物および方法
CN101484588B (zh) 2006-05-11 2013-11-06 阿尔尼拉姆医药品有限公司 抑制pcsk9基因表达的组合物和方法
JP5307708B2 (ja) 2006-06-02 2013-10-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトｉｌ−６受容体に対する高親和性抗体
US8080248B2 (en) 2006-06-02 2011-12-20 Regeneron Pharmaceuticals, Inc. Method of treating rheumatoid arthritis with an IL-6R antibody
CA2654510C (fr) 2006-06-16 2015-03-17 Regeneron Pharmaceuticals, Inc. Formulations antagonistes du vegf appropriees a une administration intravitreenne
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
US20100040610A1 (en) 2006-11-07 2010-02-18 Ayesha Sitlani Antagonists of pcsk9
US20100040611A1 (en) 2006-11-07 2010-02-18 Sparrow Carl P Antagonists of pcsk9
WO2008057459A2 (fr) 2006-11-07 2008-05-15 Merck & Co., Inc. Antagonistes de pcsk9
WO2008057458A2 (fr) * 2006-11-07 2008-05-15 Merck & Co., Inc. Antagonistes de pcsk9
US8093222B2 (en) 2006-11-27 2012-01-10 Isis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia
CA2670563A1 (fr) 2006-11-27 2008-06-05 Isis Pharmaceuticals, Inc. Procedes pour traiter l'hypercholesterolemie
CN101589143A (zh) 2006-11-27 2009-11-25 Isis药物公司 用于治疗高胆固醇血症的方法
JP5100101B2 (ja) 2006-12-12 2012-12-19 キヤノン株式会社 画像形成装置
EA200901376A1 (ru) 2007-04-13 2010-12-30 Новартис Аг Молекулы и способы модуляции пропротеинконвертазы субтилизинового/кексинового типа 9(pcsk9)
CN101687927B (zh) 2007-05-15 2013-10-30 霍夫曼-拉罗奇有限公司 针对g蛋白偶联的受体（gpcr）的抗体
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
US20100286021A1 (en) 2007-09-25 2010-11-11 Qun-Yong Zhou Methods of Modulating Prokineticin 2 for Treatment of Stress Response and Anxiety-Related Disorders
MX2010003329A (es) 2007-09-26 2010-04-27 Chugai Pharmaceutical Co Ltd Anticuerpo anti-receptor de il-6.
NZ584902A (en) 2007-10-26 2012-03-30 Schering Corp Anti-pcsk9 and methods for treating lipid and cholesterol disorders
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
AR070316A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
AR070315A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Anticuerpos 1b20 antagonistas de pcsk9
KR102057826B1 (ko) 2008-04-11 2019-12-20 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
TWI516501B (zh) * 2008-09-12 2016-01-11 禮納特神經系統科學公司 Ｐｃｓｋ９拮抗劑類
PT2331090T (pt) 2008-09-19 2018-02-07 Pfizer Formulação de anticorpo líquida estável
ES2531385T3 (es) 2008-09-19 2015-03-13 Hoffmann La Roche Formulación que comprende un anticuerpo contra la selectina P
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
WO2010068526A1 (fr) 2008-12-12 2010-06-17 Merck Sharp & Dohme Corp. Immunodosage de pcsk9
US8357371B2 (en) 2008-12-15 2013-01-22 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to PCSK9
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US20100216667A1 (en) 2008-12-17 2010-08-26 Meyer Brian K Method for determining compatibility of an active pharmaceutical ingredient with materials
AU2010221156A1 (en) 2009-03-06 2011-09-22 Genentech, Inc. Antibody formulation
JP5894913B2 (ja) 2009-06-15 2016-03-30 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｐｃｓｋ９遺伝子を標的とする、脂質で製剤化されたｄｓｒｎａ
JP2012530721A (ja) 2009-06-18 2012-12-06 ワイス・エルエルシー 小モジュール免疫薬のための凍結乾燥製剤
US20110009628A1 (en) 2009-07-08 2011-01-13 Haiyan Liu Compounds and Compositions for Modulating Lipid Levels and Methods of Preparing Same
EP2456870A1 (fr) 2009-07-21 2012-05-30 Santaris Pharma A/S Oligomères anti-sens ciblant pcsk9
WO2011028938A1 (fr) 2009-09-02 2011-03-10 Alnylam Pharmaceuticals, Inc. Procédés de diminution du taux de cholestérol sérique chez un sujet à l'aide de l'inhibition de pcsk9
US20120219558A1 (en) 2009-09-25 2012-08-30 Yan Ni Antagonists of pcsk9
WO2011039578A1 (fr) 2009-10-02 2011-04-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinaison de facteurs de risque cardiovasculaire lp(a) et d'activité de spla2 pour le diagnostic/pronostic d'une maladie/d'un événement cardiovasculaire
IN2012DN03824A (fr) 2009-10-30 2015-08-28 Merck Sharp & Dohme
CN102596249A (zh) 2009-10-30 2012-07-18 默沙东公司 Ax1和ax189 pcsk9拮抗剂和变体
EP2501408B1 (fr) 2009-11-20 2020-05-27 Biocon Limited Formulations d'anticorps
AR079336A1 (es) 2009-12-11 2012-01-18 Irm Llc Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
JO3274B1 (ar) 2009-12-24 2018-09-16 Regeneron Pharma أجسام مضادة بشرية للبروتين 4 المشابه لأجيوبيوتين البشري
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
JP5932670B2 (ja) 2010-03-11 2016-06-08 ライナット ニューロサイエンス コーポレイション ｐＨ依存性の抗原結合を有する抗体
GB201005005D0 (en) 2010-03-25 2010-05-12 Angeletti P Ist Richerche Bio New vaccine
AU2011202239C1 (en) 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
DE102010024698A1 (de) 2010-06-23 2011-12-29 Eads Deutschland Gmbh Verfahren, Vorrichtung und Anordnung zur Entfernung organischer Verschmutzung von Anströmbereichen eines Luftfahrzeugs
WO2012044999A2 (fr) 2010-10-01 2012-04-05 Ludwig Institute For Cancer Research Ltd. Multimères de protéines réversibles, et leurs procédés de production et d'utilisation
NZ609557A (en) 2010-10-06 2014-12-24 Regeneron Pharma Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
WO2012054438A1 (fr) * 2010-10-22 2012-04-26 Schering Corporation Anti-pcsk9
US9518132B2 (en) * 2010-11-09 2016-12-13 Altimab Therapeutics, Inc. Protein complexes for antigen binding and methods of use
US8771696B2 (en) 2010-11-23 2014-07-08 Regeneron Pharmaceuticals, Inc. Method of reducing the severity of stress hyperglycemia with human antibodies to the glucagon receptor
JO3756B1 (ar) 2010-11-23 2021-01-31 Regeneron Pharma اجسام مضادة بشرية لمستقبلات الجلوكاجون
WO2012076670A2 (fr) 2010-12-10 2012-06-14 Novartis Ag Formulation d'anticorps
CN103261230A (zh) 2010-12-22 2013-08-21 霍夫曼-拉罗奇有限公司 抗pcsk9抗体及使用方法
SG192117A1 (en) 2011-01-28 2013-08-30 Sanofi Sa Human antibodies to pcsk9 for use in methods of treating particular groups of subjects
WO2012109530A1 (fr) 2011-02-11 2012-08-16 Irm Llc Antagonistes de pcsk9
US8440890B1 (en) 2011-03-09 2013-05-14 Pioneer Hi Bred International Inc Maize variety inbred PH1D0D
HUE042822T2 (hu) 2011-04-20 2019-07-29 Amgen Inc Automata befecskendezõ szerkezet
AR088782A1 (es) 2011-04-29 2014-07-10 Sanofi Sa Sistemas de ensayo y metodos para identificar y caracterizar farmacos hipolipemiantes
MX367097B (es) 2011-05-02 2019-08-05 Millennium Pharm Inc FORMULACION PARA ANTICUERPO ANTI-A4ß7.
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
US20140004122A1 (en) 2011-05-10 2014-01-02 Amgen Inc. Methods for treating or preventing cholesterol related disorders
WO2012168491A1 (fr) 2011-06-10 2012-12-13 Novartis Ag Formulations pharmaceutiques d'antagonistes de pcsk9
CA2746171C (fr) 2011-07-13 2018-11-06 William Jani Bouchon de fracturation recuperable
BR112014000392A2 (pt) 2011-07-14 2017-02-21 Pfizer tratamento com anticorpos anti-pcsk9
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
HUE069234T2 (hu) 2011-09-16 2025-02-28 Regeneron Pharma Eljárások lipoprotein(a)-szint csökkentésére proprotein-konvertáz szubtilizin/kexin 9 (PCSK9) inhibitorának beadásával
AR087715A1 (es) 2011-09-16 2014-04-09 Lilly Co Eli Anticuerpos anti pcsk9 y usos de los mismos
US9943594B2 (en) 2011-10-11 2018-04-17 Sanofi Biotechnology Methods for the treatment of rheumatoid arthritis
TWI589299B (zh) 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
RS54644B1 (sr) 2012-03-08 2016-08-31 F. Hoffmann-La Roche Ag Formulacija abeta antitela
WO2013158984A1 (fr) 2012-04-19 2013-10-24 Acetylon Pharmaceuticals, Inc. Biomarqueurs permettant d'identifier des patients qui réagiront à un traitement, et traitement desdits patients
EA039663B1 (ru) 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
KR20150059638A (ko) 2012-05-25 2015-06-01 카타베이시스 파마슈티칼즈, 인코포레이티드 전구단백질 전환효소 섭틸리신/켁신 9형 저하 방법
US9540449B2 (en) 2012-08-13 2017-01-10 Regeneron Pharmaceuticals, Inc. Anti-PCSK9 antibodies with pH-dependent binding characteristics
EP2703009A1 (fr) * 2012-08-31 2014-03-05 Sanofi Traitements combinés impliquant des anticorps de la PCSK9 humaine
EP2703008A1 (fr) 2012-08-31 2014-03-05 Sanofi Anticorps humains anti-PSCK9 pour une utilisation dans des procédés de traitement des groupes de sujets particuliers
EP2706070A1 (fr) 2012-09-06 2014-03-12 Sanofi Traitements combinés impliquant des anticorps de la PCSK9 humaine
RU2538801C2 (ru) 2013-02-07 2015-01-10 Закрытое акционерное общество "Инновационный научно-производственный центр "Пептоген" ПРИМЕНЕНИЕ ТЕТРАПЕПТИДА Arg-Pro-Gly-Pro В КАЧЕСТВЕ СРЕДСТВА ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ ГИПЕРХОЛЕСТЕРИНЕМИИ, СПОСОБ ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ ГИПЕРХОЛЕСТЕРИНЕМИИ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ ДЛЯ ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ ГИПЕРХОЛЕСТЕРИНЕМИИ И СПОСОБ ЕЕ ПОЛУЧЕНИЯ
TWI682780B (zh) 2013-05-30 2020-01-21 美商再生元醫藥公司 醫藥組成物用於製造治療與ｐｃｓｋ９功能獲得性突變有關之體染色體顯性高膽固醇血症的藥物之用途
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
US10494442B2 (en) 2013-06-07 2019-12-03 Sanofi Biotechnology Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9
ES2914978T3 (es) 2013-10-11 2022-06-20 Sanofi Biotechnology Uso de un inhibidor de PCSK9 para tratar hiperlipidemia
CN118105480A (zh) 2013-11-12 2024-05-31 赛诺菲生物技术公司 用于与pcsk9抑制剂一起使用的给药方案
US9034332B1 (en) 2014-07-15 2015-05-19 Kymab Limited Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
US8945560B1 (en) 2014-07-15 2015-02-03 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US8883157B1 (en) 2013-12-17 2014-11-11 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
EA201691320A1 (ru) 2014-02-14 2016-11-30 Ридженерон Фармасьютикалз, Инк. Способы лечения пациентов с гиперхолестеринемией, которая устойчива к терапии умеренными дозами статинов
WO2015140079A1 (fr) 2014-03-17 2015-09-24 Sanofi Methodes pour traiter des sujets atteints d'hypercholestérolémie primaire qui n'est pas prise en charge de manière adéquate
KR20230074283A (ko) 2014-07-16 2023-05-26 사노피 바이오테크놀로지 이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법
CA2955304C (fr) 2014-07-16 2023-12-12 Sanofi Biotechnology Methodes de traitement de patients presentant un risque cardiovasculaire eleve avec hypercholesterolemie
EA039310B1 (ru) 2015-02-26 2022-01-12 Санофи Байотекнолоджи Способы снижения сердечно-сосудистого риска
JP2018523684A (ja) 2015-08-18 2018-08-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． リポタンパク質アフェレーシスを受けている高脂血症の患者を治療するための抗ｐｃｓｋ９阻害抗体
US10933134B2 (en) 2017-03-16 2021-03-02 Memorial Sloan Kettering Cancer Center Combination therapies for treatment of cancer
US20190031774A1 (en) 2017-06-09 2019-01-31 Sanofi Biotechnology Methods for treating hyperlipidemia in diabetic patients by administering a pcsk9 inhibitor
TW201904608A (zh) 2017-06-09 2019-02-01 法商賽諾菲生物技術公司 藉由投予ｐｃｓｋ９抑制劑治療糖尿病患者高血脂症之方法
TW201945401A (zh) 2018-03-06 2019-12-01 法商賽諾菲生物技術公司 降低心血管風險的方法

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12269897B2 (en) 2008-12-15 2025-04-08 Regeneron Pharmaceuticals, Inc. Anti-PCSK9 antibodies
US12083176B2 (en) 2011-01-28 2024-09-10 Sanofi Biotechnology Human antibodies to PCSK9 for use in methods of treating particular groups of subjects
US11673967B2 (en) 2011-07-28 2023-06-13 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-PCSK9 antibodies
US12612466B2 (en) 2011-07-28 2026-04-28 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-PCSK9 antibodies
US12606638B2 (en) 2013-11-12 2026-04-21 Sanofi Biotechnology Dosing regimens for use with PCSK9 inhibitors
US11306155B2 (en) 2014-07-16 2022-04-19 Sanofi Biotechnology Methods for treating patients with heterozygous familial hypercholesterolemia (heFH) with an anti-PCSK9 antibody
US11904017B2 (en) 2015-08-18 2024-02-20 Regeneron Pharmaceuticals, Inc. Methods for reducing or eliminating the need for lipoprotein apheresis in patients with hyperlipidemia by administering alirocumab

Also Published As

Publication number Publication date
EP2668212A2 (fr) 2013-12-04
JP2018203772A (ja) 2018-12-27
AR084939A1 (es) 2013-07-10
NI201300064A (es) 2013-12-17
IL266682A (en) 2019-07-31
PT2668212T (pt) 2018-06-28
TWI625127B (zh) 2018-06-01
TW201711698A (zh) 2017-04-01
JP2024138473A (ja) 2024-10-08
KR20140006013A (ko) 2014-01-15
RU2603481C2 (ru) 2016-11-27
WO2012101252A3 (fr) 2012-11-15
CA2825778A1 (fr) 2012-08-02
JP2017095491A (ja) 2017-06-01
KR20220136466A (ko) 2022-10-07
EP3395836A1 (fr) 2018-10-31
LT2668212T (lt) 2018-07-10
AU2012210481A1 (en) 2013-08-22
IL282219B (en) 2022-03-01
JP2022141869A (ja) 2022-09-29
JP7140800B2 (ja) 2022-09-21
SG192118A1 (en) 2013-09-30
PL3326648T3 (pl) 2021-10-11
ZA201305565B (en) 2016-01-27
US9682013B2 (en) 2017-06-20
MX385311B (es) 2025-03-18
NZ613870A (en) 2015-12-24
BR112013018877A2 (pt) 2016-10-04
ES2873273T3 (es) 2021-11-03
ES2882570T3 (es) 2021-12-02
MX367075B (es) 2019-08-05
JP6375113B2 (ja) 2018-08-15
RU2721279C2 (ru) 2020-05-18
AR084937A1 (es) 2013-07-10
EP3395836B1 (fr) 2021-04-28
US20170340515A1 (en) 2017-11-30
US20190343719A1 (en) 2019-11-14
PH12013501576A1 (en) 2013-09-30
US20250064926A1 (en) 2025-02-27
SI2668212T1 (en) 2018-08-31
KR20190090055A (ko) 2019-07-31
PH12013501577A1 (en) 2013-09-30
US11246925B2 (en) 2022-02-15
CL2013002162A1 (es) 2014-02-21
RU2013139736A (ru) 2015-03-10
US20140154262A1 (en) 2014-06-05
JP2017095490A (ja) 2017-06-01
KR20140012075A (ko) 2014-01-29
EP2668212B1 (fr) 2018-03-21
SG192117A1 (en) 2013-08-30
DOP2013000170A (es) 2013-11-30
IL227657A0 (en) 2013-09-30
CL2013002161A1 (es) 2014-03-28
AU2019229366B2 (en) 2021-09-16
ES2674600T3 (es) 2018-07-02
CN103476796A (zh) 2013-12-25
WO2012101251A1 (fr) 2012-08-02
MX347602B (es) 2017-05-03
CA2825838C (fr) 2020-10-27
CY1121236T1 (el) 2020-05-29
CO6751276A2 (es) 2013-09-16
AU2017216547A1 (en) 2017-09-07
CO6751277A2 (es) 2013-09-16
JP2020172514A (ja) 2020-10-22
NZ613867A (en) 2015-09-25
ZA201305524B (en) 2014-03-26
BR112013018740A2 (pt) 2019-01-08
AU2017216546A1 (en) 2017-09-07
PL2668212T3 (pl) 2018-08-31
MX366458B (es) 2019-07-10
CN107899010A (zh) 2018-04-13
HRP20180959T1 (hr) 2018-07-27
ECSP13012792A (es) 2013-09-30
DK2668212T3 (en) 2018-07-02
US12083176B2 (en) 2024-09-10
GT201300186A (es) 2014-04-29
RU2016142277A (ru) 2018-12-17
US20220218823A1 (en) 2022-07-14
IL266682B (en) 2021-04-29
IL227657B (en) 2019-05-30
HK1255729A1 (en) 2019-08-23
CA2825838A1 (fr) 2012-08-02
MX2013008672A (es) 2013-10-01
RU2604139C2 (ru) 2016-12-10
TW201242613A (en) 2012-11-01
CN103476797A (zh) 2013-12-25
PL3395836T3 (pl) 2021-12-13
EP3326648B1 (fr) 2021-03-10
TWI635870B (zh) 2018-09-21
RU2013139727A (ru) 2015-03-10
AU2019229366A1 (en) 2019-10-03
US9561155B2 (en) 2017-02-07
IL265707A (en) 2019-05-30
MY165159A (en) 2018-02-28
MY176600A (en) 2020-08-18
TW201242614A (en) 2012-11-01
IL282219A (en) 2021-05-31
CR20130406A (es) 2013-10-09
WO2012101252A2 (fr) 2012-08-02
PE20181052A1 (es) 2018-07-03
EP3326648A1 (fr) 2018-05-30
AR084938A1 (es) 2013-07-10
WO2012101253A1 (fr) 2012-08-02
KR20190062612A (ko) 2019-06-05
IL227658A0 (en) 2013-09-30
KR20200133826A (ko) 2020-11-30
JP2014511361A (ja) 2014-05-15
PH12021500018A1 (en) 2021-12-13
CN110711248A (zh) 2020-01-21
JP2014508142A (ja) 2014-04-03
JP6730388B2 (ja) 2020-07-29
RU2016142277A3 (fr) 2020-03-06
MX2013008669A (es) 2013-10-01
HUE039258T2 (hu) 2018-12-28
US20140178402A1 (en) 2014-06-26
NZ792724A (en) 2024-07-05
AU2012210481B2 (en) 2017-05-18
AU2012210480B2 (en) 2017-05-18
RS57339B1 (sr) 2018-08-31
RU2016142273A (ru) 2018-12-18
US20170266079A1 (en) 2017-09-21
AU2017216546B2 (en) 2019-10-03
AU2012210480A1 (en) 2013-08-22
MX2019008245A (es) 2019-09-06
PE20140372A1 (es) 2014-03-24
EP2668211A1 (fr) 2013-12-04

Similar Documents

Publication Publication Date Title
MA34923B1 (fr) Anticorps humains contre pcsk9 pour utilisation dans des procedes de traitement de groupes particuliers de sujets
MA35800B1 (fr) Compositions pharmaceutiques comprenant des anticorps humains contre pcsk9
MX375672B (es) Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9.
MX2024004495A (es) Agentes de acidos ribonucleicos de interferencia para usarse en la prevencion de eventos cardiovasculares.
WO2015073494A8 (fr) Schémas posologiques pour une utilisation avec des inhibiteurs de pcsk9
EP4252857A3 (fr) Procédés pour réduire les niveaux de lipoprotéine(a) par l'administration d'un inhibiteur de la proprotéine convertase subtilisine kexine 9 (pcsk9)
Zhao et al. Mycobacterium tuberculosis proteases and implications for new antibiotics against tuberculosis
TN2013000322A1 (en) Pharmaceutical compositions comprising human antibodies to pcsk9
Nørholt et al. Analgesic efficacy with rapidly absorbed ibuprofen sodium dihydrate in postsurgical dental pain: results from the randomized QUIKK trial.
TH158830A (th) องค์ประกอบทางเภสัชกรรมที่ประกอบด้วยแอนติบอดีต้าน pcsk9
Sagadevan Investigation of anticancer activity and mechanisms of Meso-2, 3-dimercaptosuccinic acid (DMSA) in glioblastoma cell lines
TH177074A (th) แอนติบอดีมนุษย์ต้าน pcsk9 สำหรับใช้ในวิธีการรักษาเฉพาะกลุ่มของผู้ป่วย
EA201201529A1 (ru) Комбинация ингибиторов ксантиноксидазы и статинов и ее применение
WO2014036105A3 (fr) Inhibiteurs de clivage de la mémapsine 2 pour le traitement de la maladie d'alzheimer
Gosch Are statins of value in therapy of osteoporosis?
MA38625B1 (fr) Procédé pour la préparation d'érythrocytes chargés d'une ou plusieurs substances d'intérêt pharmaceutique, et érythrocytes ainsi obtenus
TH161998A (th) แอนติบอดีต่อ pcsk9 และการใช้ของมัน